First-in-Human Phase I Clinical Trial of the Adenosine A1R/A3R Agonist AST-004 in Healthy Subjects

AST-004 is a small-molecule adenosine A1/A3 receptor agonist that has exhibited significant cerebroprotective efficacy in preclinical models of acute ischemic stroke and traumatic brain injury. The primary objectives of this clinical phase I first-in-human study were to evaluate the safety and toler...

Full description

Saved in:

Bibliographic Details
Published in:	Stroke (1970) Vol. 55; no. 12; p. 2795
Main Authors:	Manna, Lisa M, Hernandez, Juan, Hunt, Dawn E, Lakner, Géza, Matson, Mark A, Poe, Russell B, Korinek, William S, Lancey, Robert A, Liston, Theodore E
Format:	Journal Article
Language:	English
Published:	United States 01.12.2024
Subjects:	Adenosine A1 Receptor Agonists - adverse effects Adenosine A1 Receptor Agonists - pharmacokinetics Adenosine A3 Receptor Agonists - adverse effects Adenosine A3 Receptor Agonists - pharmacokinetics Adult Brain Injuries, Traumatic - prevention & control Dose-Response Relationship, Drug Double-Blind Method Female Healthy Volunteers Humans Infusions, Intravenous Male Middle Aged Stroke - prevention & control Triazoles Young Adult astrocytes half-life humans stroke brain injuries, traumatic
ISSN:	1524-4628, 1524-4628
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!